Reproductive Health Matters
Volume 13, Issue 26 , Pages 75-83 , November 2005

Women's Perspectives on Medical Abortion in Mexico, Colombia, Ecuador and Peru: A Qualitative Study

  • María Mercedes Lafaurie

      Affiliations

    • Independent consultant, Bogotá, Colombia
    • ,
  • Daniel Grossman

      Affiliations

    • Programme Associate, Population Council, Regional Office for Latin America and the Caribbean, Mexico, DF, Mexico
    • ,
  • Erika Troncoso

      Affiliations

    • Research Coordinator, Population Council, Regional Office for Latin America and the Caribbean, Mexico, DF, Mexico
    • ,
  • Deborah L Billings

      Affiliations

    • Senior Research Associate, Ipas, Mexico, DF, Mexico
    • ,
  • Susana Chávez

      Affiliations

    • Director, Centro de Promoción y Defensa de los Derechos Sexuales y Reproductivos (PROMSEX), Lima, Peru

References 

  1. Alan Guttmacher Institute. Aborto Clandestino: Una Realidad Latinoamericana. New York: AGI; 1994;
  2. World Health Organization. Unsafe abortion: global and regional estimates of the incidence of unsafe abortion and associated mortality in 2000. 4th ed. Geneva: WHO; 2004;
  3. Abortion laws of the world. At: 〈http://annualreview.law.harvard.edu/population/abortion/abortionlaws.htm〉. Accessed 28 May 2005.
  4. Global Health Council. Promises to keep. At: 〈 http://www.globalhealth.org/assets/publications/PromisesToKeep.pdf〉. Accessed 28 May 2005
  5. Billings DL, Benson J. Postabortion care in Latin America: policy and service recommendations from a decade of operations research. Health Policy and Planning. 2005;20(3):158–166
  6. Kulier R, Gülmezoglu AM, Hofmeyr GJ, et al. Medical methods for first trimester abortion (Cochrane Review). In: The Cochrane Library, Issue 1. Update Software: Oxford; 2004;
  7. Faúndes A, Santos LC, Carvalho M, et al. Post-abortion complications after interruption of pregnancy with misoprostol. Advances in Contraception. 1996;12(1):1–9
  8. Costa SH. Commercial availability of misoprostol and induced abortion in Brazil. International Journal of Gynecology and Obstetrics. 1998;63(Suppl.1):S131–S139
  9. Ferrando D. Clandestine Abortion in Peru: Facts and Figures. Lima: Centro de la Mujer Peruana, Pathfinder International; 2002;
  10. Barbosa RM, Arilha M. The Brazilian experience with Cytotec. Studies in Family Planning. 1993;24(4):236–240
  11. Walker D, Campero L, Espinoza H, et al. Deaths from complications of unsafe abortion: misclassified second trimester deaths. Reproductive Health Matters. 2004;12(24 Suppl):27–38
  12. Billings D. Misoprostol alone for early medical abortion in a Latin American clinic setting. Reproductive Health Matters. 2004;12(24 Suppl):57–64
  13. Espinoza H, Abuabara K, Ellertson C. Physicians' knowledge and opinions about medication abortion in four Latin American and Caribbean region countries. Contraception. 2004;70(2):127–133
  14. Sherris J, Bingham A, Burns MA, et al. Misoprostol use in developing countries: results from a multicountry study. International Journal of Gynecology and Obstetrics. 2005;88(1):76–81
  15. Lara D, Abuabara K, Grossman D, et al. Pharmacist provision of medical abortifacients in Mexico City. At: 〈 http://apha.confex.com/apha/132am/techprogram/paper_87582.htm〉. Accessed 28 May 2005
  16. Goicolea I. Exploring women's needs in an Amazon region of Ecuador. Reproductive Health Matters. 2001;9(17):193–202
  17. Mora M, Villareal J. Unwanted pregnancy and abortion: Bogotá, Colombia. Reproductive Health Matters. 1993;2:11–20
  18. Amuchástegui Herrera A, Rivas Zivy M. Clandestine abortion in Mexico: a question of mental as well as physical health. Reproductive Health Matters. 2002;10(19):95–102
  19. Ellertson E, Elul B, Winikoff B. Can women use medical abortion without medical supervision?. Reproductive Health Matters. 1997;9:149–161
  20. Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision?. Contraception. 2002;65:133–142
  21. Hamoda H, Ashok PW, Flett GM, et al. Analgesia requirements and predictors of analgesia use for women undergoing medical abortion up to 22 weeks of gestation. British Journal of Obstetrics and Gynaecology. 2004;111(9):996–1000
  22. Coe AB. From anti-natalist to ultra-conservative: restricting reproductive choice in Peru. Reproductive Health Matters. 2004;12(24):56–69
  23. Rodríguez Lara C. Home use: Mexican women's experience. At: 〈 http://www.medicalabortionconsortium.org/ICMA_PPT_FILES/ICMACONF/TUESDAY1/RODRIGUE/frame.htm〉. Accessed 28 May 2005
  24. Lamas M, Bissell S. Abortion and politics in Mexico: ‘context is all’. Reproductive Health Matters. 2000;8(16):10–23
  25. Billings DL, Moreno C, Ramos C, et al. Constructing access to legal abortion services in Mexico City. Reproductive Health Matters. 2002;10(19):86–94
  26. Landmark constitutional challenge in Colombia seeks to loosen one of world's most restrictive abortion laws. At: 〈http://www.womenslinkworldwide.org/pdf/co_lat_col_pressrelease.pdf〉. Accessed 10 August 2005.
  27. WHO Essential Medicines Library. At: 〈http://mednet3.who.int/EMLib/DiseaseTreatments/MedicineDetails.aspx?MedIDName=443@mifepristone-misoprostol〉. Accessed 10 August 2005.

PII: S0968-8080(05)26199-2

doi: 10.1016/S0968-8080(05)26199-2

Reproductive Health Matters
Volume 13, Issue 26 , Pages 75-83 , November 2005

Article Tools

* Image Usage & Resolution